The topic of whether intravenous magnesium sulphate should be used to prevent poor outcomes after hemorrhagic stroke should finally come to an end after researchers have found that the treatment provides no benefits compared with placebo. The study is published Online First in The Lancet. Sanne Dorhout Mees from the University Medical Center Utrecht, Netherlands, who conducted the study, explained: "The findings from MASH 2 have important implications for clinical practice. Administration of magnesium is standard practice in many centers...
Fonte: healthnews.com
Indique esta NotÃcia
Compartilhar
A PHP Error was encountered
Severity: User Warning
Message: Smarty error: unable to read resource: "indiquemat_healthnews.tpl"
Filename: libs/Smarty.class.php
Line Number: 1095
